Filing Flows › Myomo (MYO) › Guidance & outlook

Myomo (MYO) guidance and outlook

Myomo's 10-Q filed Nov 9, 2026 makes 13 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 9, 2026

• After the expiration of the interest-only period, we will re-pay the principal balance in 24 equal monthly installments.
• We do not expect to receive any proceeds from liquidation of the JV Company and there is no impact to our financial statements from the termination of the joint venture for the three and nine months ended September 30, 2026.
• We have been growing revenues while incurring net losses and negative cash flows from operations since inception and anticipate this to continue in 2026.
• We expect that our revenues will continue to grow in 2026, primarily as a result of investments to grow revenues from recurring patient sources, including generating patient referrals under our MyoConnect program, as well as from O&P practices in the U.S. and Germany, which we expect to increase operating leverage and reduce our dependence on advertising-driven direct-to-patient revenues.
• We intend to manage R&D expenses in 2026, while maintaining the pace of our R&D efforts as cash flows allow, as well as to fund a randomized controlled trial being conducted by the University of Utah (the "Utah Study").
• The decrease in the nine-month period was primarily due to lower labor expense in project management, engineering, and research partially offset with spending on the Utah Study.
• We expect the growth rate in selling, clinical and marketing expenses to be lower in 2026.
• In addition to gaining leverage on our 2025 investments, we intend to make investments in our MyoConnect referral program, including clinical sales personnel, our international operations and support for the O&P channel, as we execute our strategy to reduce our dependence on advertising-driven direct billing revenues.
• We intend to reduce the growth rate in general and administrative expenses in 2026.
• Considering our cash balance, our debt service and our operating plans discussed below, we believe there will be sufficient cash to fund our operations and capital expenditures for the next 12 months from the date of this report.
• There can be no assurance we will be successful in implementing our plans to sustain our operations and continue to conduct our business.
• For these payers, payment history is also used to estimate how much we expect to be paid upon delivery of our device and submission of an insurance claim, which determines how much revenue we recognize.

Myomo's latest quarter

Questions

What does Myomo expect?

After the expiration of the interest-only period, we will re-pay the principal balance in 24 equal monthly installments. We do not expect to receive any proceeds from liquidation of the JV Company and there is no impact to our financial statements from the termination of the joint venture for the three and nine months ended September 30, 2026. We have been growing revenues while incurring net losses and negative cash flows from operations since inception and anticipate this to continue in 2026.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.